Compare TZOO & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TZOO | ONCY |
|---|---|---|
| Founded | 1998 | 1998 |
| Country | United States | Canada |
| Employees | N/A | 29 |
| Industry | Advertising | Pharmaceuticals and Biotechnology |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 102.6M | 107.3M |
| IPO Year | 2003 | 2002 |
| Metric | TZOO | ONCY |
|---|---|---|
| Price | $11.42 | $0.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $17.50 | $7.33 |
| AVG Volume (30 Days) | 133.8K | ★ 1.1M |
| Earning Date | 04-23-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.98 | N/A |
| Revenue Next Year | $9.52 | $2,505.00 |
| P/E Ratio | $51.13 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.72 | $0.77 |
| 52 Week High | $14.00 | $1.51 |
| Indicator | TZOO | ONCY |
|---|---|---|
| Relative Strength Index (RSI) | 58.77 | 44.21 |
| Support Level | $9.78 | $0.79 |
| Resistance Level | $11.98 | $1.06 |
| Average True Range (ATR) | 0.67 | 0.06 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 57.33 | 16.10 |
Travelzoo acts as a publisher of travel and entertainment offers. It operates in four segments. Travelzoo North America segment, which is the key revenue driver, consists of operations in Canada and the U.S.; Travelzoo Europe segment consists of operations in France, Germany, Spain, and the U.K.; Jack's Flight Club segment consists of subscription revenue from premium members to access and receive flight deals from Jack's Flight Club via email or via Android or Apple mobile applications; and New Initiatives consists of Travelzoo's licensing activities in Asia Pacific territories. It derives its revenue through advertising fees including listing fees paid by travel, entertainment, and local businesses to advertise their offers on the company's media properties.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.